COVID-19 teleassistance and teleconsultation: a matched case-control study (MIRATO project, Lombardy, Italy).
chronic disease
outcome
rehabilitation
symptoms
teleassistance
teleconsultation
telemedicine
telemonitoring
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
10
2022
accepted:
31
07
2023
medline:
30
8
2023
pubmed:
30
8
2023
entrez:
30
8
2023
Statut:
epublish
Résumé
During the COVID-19 pandemic, telemedicine has been recognised as a powerful modality to shorten the length of hospital stay and to free up beds for the sicker patients. Lombardy, and in particular the areas of Bergamo, Brescia, and Milan, was one of the regions in Europe most hit by the COVID-19 pandemic. The primary aim of the MIRATO project was to compare the incidence of severe events (hospital readmissions and mortality) in the first three months after discharge between COVID-19 patients followed by a Home-Based Teleassistance and Teleconsultation (HBTT group) program and those discharged home without Telemedicine support (non-HBTT group). The study was designed as a matched case-control study. The non-HBTT patients were matched with the HBTT patients for sex, age, presence of COVID-19 pneumonia and number of comorbidities. After discharge, the HBTT group underwent a telecare nursing and specialist teleconsultation program at home for three months, including monitoring of vital signs and symptoms. Further, in this group we analysed clinical data, patients' satisfaction with the program, and quality of life. Four hundred twenty-two patients per group were identified for comparison. The median age in both groups was 70 ± 11 years (62% males). One or more comorbidities were present in 86% of the HBTT patients and 89% in the non-HBTT group ( Compared to usual care, an HBTT program can reduce severe events (hospital admissions/mortality) at 3-months from discharge and improve symptoms and quality of life. www.ClinicalTrials.gov, NCT04898179.
Sections du résumé
Background
UNASSIGNED
During the COVID-19 pandemic, telemedicine has been recognised as a powerful modality to shorten the length of hospital stay and to free up beds for the sicker patients. Lombardy, and in particular the areas of Bergamo, Brescia, and Milan, was one of the regions in Europe most hit by the COVID-19 pandemic. The primary aim of the MIRATO project was to compare the incidence of severe events (hospital readmissions and mortality) in the first three months after discharge between COVID-19 patients followed by a Home-Based Teleassistance and Teleconsultation (HBTT group) program and those discharged home without Telemedicine support (non-HBTT group).
Methods
UNASSIGNED
The study was designed as a matched case-control study. The non-HBTT patients were matched with the HBTT patients for sex, age, presence of COVID-19 pneumonia and number of comorbidities. After discharge, the HBTT group underwent a telecare nursing and specialist teleconsultation program at home for three months, including monitoring of vital signs and symptoms. Further, in this group we analysed clinical data, patients' satisfaction with the program, and quality of life.
Results
UNASSIGNED
Four hundred twenty-two patients per group were identified for comparison. The median age in both groups was 70 ± 11 years (62% males). One or more comorbidities were present in 86% of the HBTT patients and 89% in the non-HBTT group (
Conclusions
UNASSIGNED
Compared to usual care, an HBTT program can reduce severe events (hospital admissions/mortality) at 3-months from discharge and improve symptoms and quality of life.
Clinical trial registration
UNASSIGNED
www.ClinicalTrials.gov, NCT04898179.
Identifiants
pubmed: 37645519
doi: 10.3389/fcvm.2023.1062232
pmc: PMC10461473
doi:
Banques de données
ClinicalTrials.gov
['NCT04898179']
Types de publication
Journal Article
Langues
eng
Pagination
1062232Informations de copyright
© 2023 Bernocchi, Crotti, Beato, Bonometti, Giudici, Bertolaia, Perger, Remuzzi, Bachetti, La Rovere, Dalla Vecchia, Angeli, Parati, Borghi, Vitacca and Scalvini.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Environ Res. 2021 Jun;197:111097
pubmed: 33811866
Aust J Gen Pract. 2022 Aug;51(8):626-629
pubmed: 35908757
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Life (Basel). 2022 May 24;12(6):
pubmed: 35743804
Int J Cardiol. 2009 Jan 9;131(2):192-9
pubmed: 18222552
Acta Myol. 2023 Mar 31;42(1):14-23
pubmed: 37091527
Eur J Cardiovasc Nurs. 2020 Aug;19(6):486-494
pubmed: 32380858
Scand J Caring Sci. 2020 Sep;34(3):675-683
pubmed: 31657054
J Telemed Telecare. 2018 Aug;24(7):500-507
pubmed: 28537509
Telemed J E Health. 2022 May;28(5):720-727
pubmed: 34402684
Front Psychol. 2022 Aug 10;13:909417
pubmed: 36033038
AMIA Annu Symp Proc. 2023 Apr 29;2022:1108-1117
pubmed: 37128455
Sci Data. 2022 Jul 30;9(1):454
pubmed: 35908040
J Med Internet Res. 2021 Apr 6;23(4):e24552
pubmed: 33769945
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Telemed J E Health. 2021 Oct;27(10):1194-1199
pubmed: 33264071
Ethics Med Public Health. 2021 Mar;16:100612
pubmed: 33283033
Eur Respir J. 2009 Feb;33(2):411-8
pubmed: 18799512
BMJ Open Qual. 2021 Sep;10(3):
pubmed: 34518302
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
J Med Syst. 2020 Jun 15;44(7):132
pubmed: 32542571
J Epidemiol Biostat. 2001;6(3):305-16
pubmed: 11437095
JAMA. 2021 Jan 19;325(3):304-306
pubmed: 33315057
Ir J Med Sci. 2021 Feb;190(1):1-10
pubmed: 32642981
Telemed J E Health. 2023 Feb;29(2):298-303
pubmed: 35687378
JMIR Med Inform. 2022 Nov 28;10(11):e40469
pubmed: 36265039
BMJ Support Palliat Care. 2021 Jun 29;:
pubmed: 34187878
Int J Environ Res Public Health. 2023 Jan 06;20(2):
pubmed: 36673792
Health Informatics J. 2023 Apr-Jun;29(2):14604582231167431
pubmed: 37076954
J Med Internet Res. 2023 Mar 27;25:e44711
pubmed: 36972122
Curr Med Res Opin. 2023 Jun;39(6):827-832
pubmed: 37129909
G Ital Cardiol (Rome). 2021 Nov;22(11):931-941
pubmed: 34709233
Phys Med Rehabil Clin N Am. 2021 May;32(2):405-418
pubmed: 33814065